1997
DOI: 10.1002/(sici)1096-9098(199709)66:1<55::aid-jso12>3.0.co;2-n
|View full text |Cite
|
Sign up to set email alerts
|

Update on active specific immunotherapy with melanoma vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

1998
1998
2014
2014

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(5 citation statements)
references
References 74 publications
0
5
0
Order By: Relevance
“…Immunization techniques against tumor antigens have been successful in protecting animals against the subsequent growth of tumors that express the same antigens, findings which support the immunosurveillance theory that was originally proposed by Thomas (21) and Burnet (22). Vaccination pro- cedures based on this information are currently undergoing clinical trials for selected human malignancies (23,24).…”
Section: Discussionmentioning
confidence: 62%
“…Immunization techniques against tumor antigens have been successful in protecting animals against the subsequent growth of tumors that express the same antigens, findings which support the immunosurveillance theory that was originally proposed by Thomas (21) and Burnet (22). Vaccination pro- cedures based on this information are currently undergoing clinical trials for selected human malignancies (23,24).…”
Section: Discussionmentioning
confidence: 62%
“…The hypothesis that such regression may be associated with vitiligo provides a rational basis for melanocyte antigen‐directed immunotherapy 108 . Successful active specific immunotherapy would provide a host with tumor antigen in the correct context to allow generation of an immune response 109,110 …”
Section: Enhancing Treatment Effectivenessmentioning
confidence: 99%
“…Besides, several immunological modifications have been described with the metronomic cyclophosphamide [24,[30][31][32][33] as summarized in Table 3. Immunomodulation is interesting in immunodepressed patients [13,34,35] with immunogenic cancer [30].…”
Section: Discussionmentioning
confidence: 99%
“…Immunomodulation is interesting in immunodepressed patients [13,34,35] with immunogenic cancer [30]. Decrease of interleukin 10 and TGF beta [30] Associating immunomodulation and antiangiogenic action may explain the disease's stabilisation.…”
Section: Discussionmentioning
confidence: 99%